Bioheng Therapeutics
PrivateLast Round
Series B
Mar 24, 2021
Total Funding Raised
$97.97M
Company Overview
Bioheng Therapeutics operates in Healthcare & Life Sciences and is based in Nanjing. Its latest recorded funding round was a Series B round in March 2021.
Bioheng Therapeutics is a biopharmaceutical company that develops allogeneic, off-the-shelf universal CAR-T cell therapies for the treatment of cancer and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bioheng Therapeutics Comparables
Compare Bioheng Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allotera Therapeutics | 89% | |
| AvenCell | 82% | |
| Century Therapeutics | 78% |
For institutional investors. Book with your work email.
Bioheng Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 24, 2021 | ||||
| Series A | Feb 14, 2019 | ||||
| Angel | Apr 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Bioheng Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Series B |
| Hillhouse Investment | Series B |
| Lanchi Ventures | Series B |
| GL Ventures | Series B |
| Octagon Capital Advisors | Series B |
| BlueRun Ventures | Series B |
| Octagon Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2025
Presented latest clinical data for CAR-T product CTD402 at an event.
For institutional investors. Book with your work email.
Bioheng Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Bioheng Therapeutics's valuation, stock price, and market status.
Is Bioheng Therapeutics a public or private company?
Bioheng Therapeutics is a private company.
What is the current stock price of Bioheng Therapeutics?
Bioheng Therapeutics is a private company, so its shares have no public market price. Caplight tracks Bioheng Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bioheng Therapeutics worth (valuation)?
Valuation information for Bioheng Therapeutics is not publicly available.
Can I buy Bioheng Therapeutics stock?
Bioheng Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bioheng Therapeutics's last funding round?
Bioheng Therapeutics's most recent funding round was Series B on March 24, 2021.
Who are the main investors in Bioheng Therapeutics?
Key investors in Bioheng Therapeutics include Hillhouse Investment, GL Ventures, Octagon Capital Advisors, Octagon Capital, Decheng Capital.
Will Bioheng Therapeutics IPO soon?
No public IPO plans have been announced for Bioheng Therapeutics.
How can I track Bioheng Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Bioheng Therapeutics's shares on secondary markets.